HPC1/RNASEL mediates apoptosis of prostate cancer cells treated with 2′,5′-oligoadenylates, topoisomerase I inhibitors, and tumor necrosis factor-related apoptosis-inducing ligand

Cancer Research

Volumn 64, Issue 24, 2004, Pages 9144-9151

  Malathi, Krishnamurthy ^a   Paranjape, Jayashree M ^a   Ganapathi, Ram ^b   Silverman, Robert H ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',5' OLIGOADENYLIC ACID; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; CAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR; HP 68; INTERFERON; RIBONUCLEASE L; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; TOPOTECAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ALLELE; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; GENE; GENE AMPLIFICATION; HPC1 GENE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; RNASEL GENE; SIGNAL TRANSDUCTION;

ADENINE NUCLEOTIDES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CAMPTOTHECIN; DNA TOPOISOMERASES, TYPE I; DRUG SYNERGISM; ENDORIBONUCLEASES; ENZYME INHIBITORS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MAP KINASE KINASE 4; MEMBRANE GLYCOPROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; OLIGORIBONUCLEOTIDES; PROSTATIC NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TOPOTECAN; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 10844279211     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2226     Document Type: Article

References (45)

1. Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat Rev Cancer 2002;2:331-41.
2. Schaid DJ. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004;13:103-21.
3. Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 1992;89:3367-71.
4. Nelson WG, De Marzo AM, Isaacs WB, Prostate cancer. N Engl J Med 2003;349:366-81.
5. Smith JR, Freije D, Carpten JD, et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science (Wash DC) 1996;274:1371-4.
6. Carpten J, Nupponen N, Isaacs S, et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 2002;30:181-4.
7. Rokman A, Ikonen T, Seppala EH, et al. Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am J Hum Genet 2002;70:1299-304.
8. Rennert H, Bercovich D, Hubert A. et al. A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. Am J Hum Genet 2002;71:981-4.
9. Casey G, Neville PJ, Plummer SJ, et al. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet 2002;32:581-3.
10. Silverman RH. Implications for RNase L in prostate cancer biology. Biochemistry 2003;42:1805-12.
11. Downing SR, Hennessy KT, Abe M, et al. Mutations in ribonuclease L gene do not occur at a greater frequency in patients with familial prostate cancer compared with patients with sporadic prostate cancer. Clin Prostate Cancer 2003;2:177-80.
12. Kotar K, Hamel N, Thiffault I, Foulkes WD. RNASEL 471delAAAG allele and prostate cancer in Ashkenazi Jewish men. J Med Genet 2003;40:e22.
13. Zhou A, Hassel BA, Silverman RH. Expression cloning of 2-5A dependent RNAase: a uniquely regulated mediator of interferon action. Cell 1993;72:753-65.
14. Hassel BA, Zhou A, Sotomayor C, Maran A, Silverman RH. A dominant negative mutant of 2-5A-dependent RNase suppresses antiproliferative and antiviral effects of interferon. EMBO J 1993;12:3297-304.
15. Kerr IM, Brown RE. pppA2′p5′A2′p5′ A: an inhibitor of protein synthesis synthesized with an enzyme fraction from interferon-treated cells. Proc Natl Acad Sci USA 1978;75:256-60.
16. Zhou A, Paranjape J, Brown TL, et al. Interferon action and apoptosis are detective in mice devoid of 2′,5′-oligoadenylate-dependent RNase L. EMBO J 1997;16:6355-63.
17. Dong B, Silverman RH. 2-5A-dependent RNase molecules dimerize during activation by 2-5A. J Biol Chem 1995;270:4133-7.
18. Bisbal C, Martinand C, Silhol M, Lebleu B, Salehzada T. Cloning and characterization of a RNAse L inhibitor. A new component of the interferon-regulated 2-5A pathway. J Biol Chem 1995;270:13308-17.
19. Zimmerman C, Klein KC, Kiser PK, et al. Identification of a host protein essential for assembly of immature HIV-1 capsids. Nature (Lond) 2002;415:88-92.
20. Dong J, Lai R, Nielsen K, et al. The essential ATP-binding cassette protein RL11 functions in translation by promoting preinitiation complex assembly. J Biol Chem 2004;279:42157-68.
21. Iordanov MS, Pribnow D, Magun JL, et al. Ribotoxic stress response: activation of the stress-activated protein kinase JNK1 by inhibitors of the peptidyl transferase reaction and by sequence-specific RNA damage to the alpha-sarcin/ricin loop in the 28S rRNA. Mol Cell Biol 1997;17:3373-81.
22. 2-terminal kinase by double-stranded RNA and encephalomyocarditis virus: involvement of RNase L, protein kinase R, and alternative pathways. Mol Cell Biol 2000;20:617-27.
23. 2-terminal kinase. J Biol Chem 2004;279:1123-31.
24. Rusch L, Zhou A, Silverman RH. Caspase-dependent apoptosis by 2′,5′-oligoadenylate activation of RNase L is enhanced by IFN-beta. J Interferon Cytokine Res 2000;20:1091-100.
25. Xiang Y, Wang Z, Murakami J, et al. Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2′,5′- oligoadenylates. Cancer Res 2003;63:6795-801.
26. Nupponen NN, Wallen MJ, Ponciano D, et al. Mutational analysis of susceptibility genes RNASEL/HPC1, ELAC2/HPC2, and MSR1 in sporadic prostate cancer. Genes Chromosomes Cancer 2004;39:119-25.
27. Thomas CJ, Rahier NJ, Hecht SM. Camptothecin: current perspectives. Bioorg Med Chem 2004;12:1585-604.
28. Costa-Pereira AP, Cotter TG. Camptothecin sensitizes androgen-independent prostate cancer cells to anti-Fas-induced apoptosis. Br J Cancer 1999;80:371-8.
29. Costa-Pereira AP, McKenna SL, Cotter TG. Activation of SAPK/JNK by camptothecin sensitizes androgen-independent prostate cancer cells to Fas-induced apoptosis. Br J Cancer 2000;82:1827-34.
30. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-82.
31. Pitti RM, Marsters SA, Ruppert S, et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996;271:12687-90.
32. Kim K, Fisher MJ, Xu SQ, el-Deiry WS. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 2000;6:335-46.
33. Almasan A, Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 2003;14:337-8.
34. Herr I, Wilhelm D, Bohler T, Angel P, Debatin KM. JNK/SAPK activity is not sufficient for anticancer therapy-induced apoptosis involving CD95-L, TRAIL and TNF-alpha. Int J Cancer 1999;29:417-24.
35. van Ophoven A, Ng CP, Patel B, Bonavida B, Belldegrun A. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) for treatment of prostate cancer: first results and review of the literature. Prostate Cancer Prostatic Dis 1999;2:227-33.
36. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Investig 1999;104:155-62.
37. Ray S, Almasan A. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11. Cancer Res 2003;63:4713-23.
38. Griffith TS, Kemp TJ. The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis. Cancer Chemother Pharmacol 2003;52:175-84.
39. Gliniak B, Le T. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res 1999;59:6153-8.
40. Chinnaiyan AM, Prasad U, Shankar S, et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci USA 2000;97:1754-9.
41. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science (Wash DC) 2002;296:550-3.
42. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003;5:834-9.
43. Bain J, McLauchlan H, Elliott M, Cohen P. The specificities of protein kinase inhibitors: an update. Biochem J 2003;371:199-204.
44. Lei K, Davis RJ. JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc Natl Acad Sci USA 2003;100:2432-7.
45. Choy H, Kim JS, Pyo H, MacRae R. Topoisomerase I inhibitors in the combined modality therapy of lung cancer. Clin Lung Cancer 2001;2:S34-40.